What Is Victoza?

1. What the Label Covers

The current Victoza label, revised October 2025, lists two indications. The first is glucose control as an adjunct to diet and exercise in adults and children aged 10 and older with type 2 diabetes. The second is reducing the risk of major adverse cardiovascular events, meaning cardiovascular death, non-fatal heart attack, or non-fatal stroke, in adults with type 2 diabetes and established cardiovascular disease.

Weight reduction is not on the label. Liraglutide does reduce weight, and the same molecule is approved for that as Saxenda at a higher dose, but Victoza’s trials were run for blood sugar and the label reflects them. The label also says not to combine Victoza with any other liraglutide product.

2. The Dose Ladder and the Pen

Children follow the same three doses, with each step held for at least a week and escalated only if glucose control requires it. The injection goes under the skin of the abdomen, thigh, or upper arm, at any time of day, independently of meals. A missed dose is simply skipped; the label says to resume with the next scheduled dose and not to take an extra one. When used with insulin, the two are separate injections and are never mixed.

The pen holds 18 mg in 3 mL and delivers 0.6, 1.2, or 1.8 mg per click sequence. At 1.8 mg daily, one pen lasts ten days.

3. LEADER: The Cardiovascular Evidence

LEADER randomised 9,340 adults with type 2 diabetes and high cardiovascular risk to liraglutide or placebo on top of standard care, and followed them for a median of 3.8 years. It was designed to show liraglutide did not increase cardiovascular events; it showed a reduction.

Heart attack, stroke, and heart failure hospitalisation were each lower on liraglutide but not significantly so on their own. The result added the cardiovascular indication to the label in 2017. For context, semaglutide’s SUSTAIN-6 later reported a hazard ratio of 0.74 and tirzepatide’s SURPASS-CVOT 0.92 against an active comparator; the trials differ in populations and design and are not a ranking.

4. Children and Adolescents

Victoza was the first GLP-1 drug approved for type 2 diabetes in patients under 18. The Ellipse trial randomised 134 children and adolescents aged 10 to 17 to liraglutide or placebo for 26 weeks, with a 26-week open-label extension, and found a greater fall in HbA1c on liraglutide. The label notes that hypoglycemia was more frequent in pediatric patients on Victoza regardless of whether they used insulin or metformin, which is why the pediatric ladder escalates only when glucose control requires it.

5. Safety

The label opens with the boxed warning on thyroid C-cell tumors, seen in rodents, and contraindicates Victoza for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. The warnings that follow are the class set: acute pancreatitis, hypoglycemia when combined with insulin or a sulfonylurea, hypersensitivity reactions, acute kidney injury from dehydration, severe gastrointestinal reactions, and acute gallbladder disease, which occurred in 3.1% of LEADER patients on liraglutide against 1.9% on placebo. Nausea is the most common side effect and is concentrated in the first weeks, which is the reason for the 0.6 mg starting week.

6. Generic Liraglutide

On December 23, 2024, FDA approved the first generic liraglutide injection referencing Victoza, from Hikma, in the same 18 mg/3 mL pen. DailyMed now lists generic liraglutide for type 2 diabetes from several other manufacturers as well, and separately lists generics referencing Saxenda. A generic must match the brand’s dose, route, and labeling, so the ladder, the pen, and the warnings above apply to it unchanged. What changes is the price and the name on the box, and for a person keeping a record the product name is worth writing down exactly as dispensed.

7. Victoza Among the Other Brands

The weekly drugs produce more weight loss and need fewer injections. Victoza’s advantages are its price as a generic, the longest post-marketing record in the class, and a 13-hour half-life that clears in days rather than weeks.

For a record, the entry is product, date, milligrams, and injection site. How GLP-1 tracking works covers what to keep.

8. What Is Victoza FAQ

• What is Victoza in simple terms?

  Victoza is a once-daily injection of liraglutide, a GLP-1 receptor agonist, for type 2 diabetes. It lowers blood sugar by increasing insulin when glucose is high, reducing glucagon, and slowing the stomach. It also reduces heart attacks, strokes, and cardiovascular deaths in adults with type 2 diabetes and cardiovascular disease, which is its second labeled indication.

• How is Victoza dosed?

  0.6 mg daily for one week, then 1.2 mg. If more glucose control is needed, 1.8 mg after at least a week on 1.2 mg. The 0.6 mg week is for tolerability only. It is injected under the skin of the abdomen, thigh, or upper arm at any time of day, with or without food.

• Is there a generic Victoza?

  Yes. FDA approved the first generic liraglutide injection referencing Victoza on December 23, 2024, from Hikma, and DailyMed now lists generic liraglutide for type 2 diabetes from several manufacturers. The doses, pen, and warnings are the same.

• What is the difference between Victoza and Saxenda?

  The same molecule at different doses for different indications. Victoza is 0.6 to 1.8 mg for type 2 diabetes. Saxenda is 0.6 to 3 mg for weight reduction. The labels say not to use two liraglutide products together.

• How does Victoza compare with Ozempic?

  Ozempic is semaglutide, a related molecule injected weekly rather than daily. Both carry a cardiovascular indication in type 2 diabetes: Victoza from LEADER (hazard ratio 0.87), Ozempic from SUSTAIN-6 (0.74), in different trials that cannot be compared directly. In head-to-head trials in obesity, semaglutide produced considerably more weight loss.

9. Sources